Matches in SemOpenAlex for { <https://semopenalex.org/work/W2026612395> ?p ?o ?g. }
Showing items 1 to 94 of
94
with 100 items per page.
- W2026612395 endingPage "289.e1" @default.
- W2026612395 startingPage "283" @default.
- W2026612395 abstract "The dose of bevacizumab necessary to optimally inhibit tumor angiogenesis in advanced renal cell carcinoma is unknown. In this phase II trial, we evaluated the efficacy and safety of 2 escalated doses of bevacizumab in patients with advanced clear cell renal carcinoma.Eligible patients had metastatic or locally advanced unresectable clear cell renal carcinoma. Patients who were previously untreated or who had previously received vascular endothelial growth factor receptor (VEGFR)-targeted therapy were eligible and were considered separately in the efficacy evaluation. Two doses of bevacizumab were evaluated in sequential cohorts: 15 mg/kg every 2 weeks and 15 mg/kg weekly. The initial reevaluation was at 8 weeks; responding and stable patients continued treatment, with reevaluations every 8 weeks until tumor progression or unacceptable toxicity occurred.One hundred nineteen eligible patients were enrolled and received bevacizumab 15 mg/kg every 2 weeks (n = 61) or bevacizumab 15 mg/kg weekly (n = 58). Seventy patients were previously untreated with VEGFR-targeted therapy. In previously untreated patients, the overall response rate was 19%, with a median progression-free survival (PFS) of 7.8 months. Less activity was seen in patients previously treated with VEGFR-targeted agents (overall response rate, 4%; median PFS, 3.7 months). There was no suggestion of any difference in efficacy between the 2 dose levels tested. Both dose levels were tolerated well by most patients, with a spectrum of toxicity typical for bevacizumab. Grade 3/4 proteinuria was more frequent with both of these escalated doses, particularly with 15 mg/kg weekly.Although administration of escalated doses of bevacizumab was feasible in patients with advanced clear cell renal carcinoma, there was no suggestion that these doses were more efficacious than bevacizumab administered at the standard dose of 10 mg/kg every 2 weeks." @default.
- W2026612395 created "2016-06-24" @default.
- W2026612395 creator A5004557221 @default.
- W2026612395 creator A5045139636 @default.
- W2026612395 creator A5053359739 @default.
- W2026612395 creator A5063636021 @default.
- W2026612395 creator A5065917441 @default.
- W2026612395 creator A5079398298 @default.
- W2026612395 date "2013-09-01" @default.
- W2026612395 modified "2023-09-27" @default.
- W2026612395 title "High-Dose Bevacizumab in the Treatment of Patients With Advanced Clear Cell Renal Carcinoma: A Phase II Trial of the Sarah Cannon Oncology Research Consortium" @default.
- W2026612395 cites W1970941392 @default.
- W2026612395 cites W1999966467 @default.
- W2026612395 cites W2019607817 @default.
- W2026612395 cites W2029126579 @default.
- W2026612395 cites W2046507292 @default.
- W2026612395 cites W2104540972 @default.
- W2026612395 cites W2115005218 @default.
- W2026612395 cites W2143813821 @default.
- W2026612395 cites W2149456801 @default.
- W2026612395 cites W2160476851 @default.
- W2026612395 cites W2162424705 @default.
- W2026612395 cites W4293241248 @default.
- W2026612395 doi "https://doi.org/10.1016/j.clgc.2013.04.014" @default.
- W2026612395 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23684421" @default.
- W2026612395 hasPublicationYear "2013" @default.
- W2026612395 type Work @default.
- W2026612395 sameAs 2026612395 @default.
- W2026612395 citedByCount "6" @default.
- W2026612395 countsByYear W20266123952014 @default.
- W2026612395 countsByYear W20266123952015 @default.
- W2026612395 countsByYear W20266123952016 @default.
- W2026612395 countsByYear W20266123952021 @default.
- W2026612395 crossrefType "journal-article" @default.
- W2026612395 hasAuthorship W2026612395A5004557221 @default.
- W2026612395 hasAuthorship W2026612395A5045139636 @default.
- W2026612395 hasAuthorship W2026612395A5053359739 @default.
- W2026612395 hasAuthorship W2026612395A5063636021 @default.
- W2026612395 hasAuthorship W2026612395A5065917441 @default.
- W2026612395 hasAuthorship W2026612395A5079398298 @default.
- W2026612395 hasConcept C126322002 @default.
- W2026612395 hasConcept C126894567 @default.
- W2026612395 hasConcept C141071460 @default.
- W2026612395 hasConcept C143998085 @default.
- W2026612395 hasConcept C167734588 @default.
- W2026612395 hasConcept C2776694085 @default.
- W2026612395 hasConcept C2777025900 @default.
- W2026612395 hasConcept C2777472916 @default.
- W2026612395 hasConcept C2777802072 @default.
- W2026612395 hasConcept C2779561371 @default.
- W2026612395 hasConcept C2780091579 @default.
- W2026612395 hasConcept C2780739268 @default.
- W2026612395 hasConcept C29730261 @default.
- W2026612395 hasConcept C31760486 @default.
- W2026612395 hasConcept C71924100 @default.
- W2026612395 hasConcept C90924648 @default.
- W2026612395 hasConceptScore W2026612395C126322002 @default.
- W2026612395 hasConceptScore W2026612395C126894567 @default.
- W2026612395 hasConceptScore W2026612395C141071460 @default.
- W2026612395 hasConceptScore W2026612395C143998085 @default.
- W2026612395 hasConceptScore W2026612395C167734588 @default.
- W2026612395 hasConceptScore W2026612395C2776694085 @default.
- W2026612395 hasConceptScore W2026612395C2777025900 @default.
- W2026612395 hasConceptScore W2026612395C2777472916 @default.
- W2026612395 hasConceptScore W2026612395C2777802072 @default.
- W2026612395 hasConceptScore W2026612395C2779561371 @default.
- W2026612395 hasConceptScore W2026612395C2780091579 @default.
- W2026612395 hasConceptScore W2026612395C2780739268 @default.
- W2026612395 hasConceptScore W2026612395C29730261 @default.
- W2026612395 hasConceptScore W2026612395C31760486 @default.
- W2026612395 hasConceptScore W2026612395C71924100 @default.
- W2026612395 hasConceptScore W2026612395C90924648 @default.
- W2026612395 hasIssue "3" @default.
- W2026612395 hasLocation W20266123951 @default.
- W2026612395 hasLocation W20266123952 @default.
- W2026612395 hasOpenAccess W2026612395 @default.
- W2026612395 hasPrimaryLocation W20266123951 @default.
- W2026612395 hasRelatedWork W1977544516 @default.
- W2026612395 hasRelatedWork W2010133921 @default.
- W2026612395 hasRelatedWork W2013969274 @default.
- W2026612395 hasRelatedWork W2026612395 @default.
- W2026612395 hasRelatedWork W2037672098 @default.
- W2026612395 hasRelatedWork W2089902323 @default.
- W2026612395 hasRelatedWork W2269916035 @default.
- W2026612395 hasRelatedWork W2317731611 @default.
- W2026612395 hasRelatedWork W2745173119 @default.
- W2026612395 hasRelatedWork W3087612503 @default.
- W2026612395 hasVolume "11" @default.
- W2026612395 isParatext "false" @default.
- W2026612395 isRetracted "false" @default.
- W2026612395 magId "2026612395" @default.
- W2026612395 workType "article" @default.